Based on the cognitive deterioration, we performed a CSF analysis examining the validated AD CSF biomarkers Aβ1-40, Aβ1-42, total tau (T-tau), and phosphorylated tau (P-tau181) as well as 14-3-3 and total prion protein (t-PrP), that revealed an AD profile with decreased Aβ42/Aβ40 ratio and increased T-tau (T-Tau 634 ng/L (normal range <400), P-Tau 75 ng/L (<80), Aβ42 546 ng/L (>330), Aβ40 12,456 ng/L (>330), Aβ42/Aβ40 ratio 0.043 (>0.7)). This evidence concerns the gene MAPT and Alzheimer disease.